ID   LCAT_RAT                Reviewed;         440 AA.
AC   P18424; O35849;
DT   01-NOV-1990, integrated into UniProtKB/Swiss-Prot.
DT   17-JUN-2020, sequence version 2.
DT   29-MAY-2024, entry version 134.
DE   RecName: Full=Phosphatidylcholine-sterol acyltransferase;
DE            EC=2.3.1.43 {ECO:0000269|PubMed:14636062, ECO:0000269|PubMed:8820107, ECO:0000269|PubMed:9219904};
DE   AltName: Full=1-alkyl-2-acetylglycerophosphocholine esterase;
DE            EC=3.1.1.47 {ECO:0000250|UniProtKB:P04180};
DE   AltName: Full=Lecithin-cholesterol acyltransferase {ECO:0000303|PubMed:14636062};
DE   AltName: Full=Phospholipid-cholesterol acyltransferase;
DE   AltName: Full=Platelet-activating factor acetylhydrolase {ECO:0000250|UniProtKB:P04180};
DE            Short=PAF acetylhydrolase;
DE   Flags: Precursor;
GN   Name=Lcat;
OS   Rattus norvegicus (Rat).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Glires; Rodentia; Myomorpha; Muroidea; Muridae;
OC   Murinae; Rattus.
OX   NCBI_TaxID=10116;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RX   PubMed=2402469; DOI=10.1093/nar/18.17.5308;
RA   Meroni G., Malgaretti N., Magnaghi P., Taramelli R.;
RT   "Nucleotide sequence of the cDNA for lecithin-cholesterol acyl transferase
RT   (LCAT) from the rat.";
RL   Nucleic Acids Res. 18:5308-5308(1990).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA], CATALYTIC ACTIVITY, AND SUBCELLULAR LOCATION.
RC   STRAIN=Sprague-Dawley, and Wistar; TISSUE=Liver;
RX   PubMed=9219904; DOI=10.1016/s0005-2760(97)00055-6;
RA   Wang J., Gebre A.K., Anderson R.A., Parks J.S.;
RT   "Cloning and in vitro expression of rat lecithin:cholesterol
RT   acyltransferase.";
RL   Biochim. Biophys. Acta 1346:207-211(1997).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RC   STRAIN=Brown Norway;
RX   PubMed=15057822; DOI=10.1038/nature02426;
RA   Gibbs R.A., Weinstock G.M., Metzker M.L., Muzny D.M., Sodergren E.J.,
RA   Scherer S., Scott G., Steffen D., Worley K.C., Burch P.E., Okwuonu G.,
RA   Hines S., Lewis L., Deramo C., Delgado O., Dugan-Rocha S., Miner G.,
RA   Morgan M., Hawes A., Gill R., Holt R.A., Adams M.D., Amanatides P.G.,
RA   Baden-Tillson H., Barnstead M., Chin S., Evans C.A., Ferriera S.,
RA   Fosler C., Glodek A., Gu Z., Jennings D., Kraft C.L., Nguyen T.,
RA   Pfannkoch C.M., Sitter C., Sutton G.G., Venter J.C., Woodage T., Smith D.,
RA   Lee H.-M., Gustafson E., Cahill P., Kana A., Doucette-Stamm L.,
RA   Weinstock K., Fechtel K., Weiss R.B., Dunn D.M., Green E.D.,
RA   Blakesley R.W., Bouffard G.G., De Jong P.J., Osoegawa K., Zhu B., Marra M.,
RA   Schein J., Bosdet I., Fjell C., Jones S., Krzywinski M., Mathewson C.,
RA   Siddiqui A., Wye N., McPherson J., Zhao S., Fraser C.M., Shetty J.,
RA   Shatsman S., Geer K., Chen Y., Abramzon S., Nierman W.C., Havlak P.H.,
RA   Chen R., Durbin K.J., Egan A., Ren Y., Song X.-Z., Li B., Liu Y., Qin X.,
RA   Cawley S., Cooney A.J., D'Souza L.M., Martin K., Wu J.Q.,
RA   Gonzalez-Garay M.L., Jackson A.R., Kalafus K.J., McLeod M.P.,
RA   Milosavljevic A., Virk D., Volkov A., Wheeler D.A., Zhang Z., Bailey J.A.,
RA   Eichler E.E., Tuzun E., Birney E., Mongin E., Ureta-Vidal A., Woodwark C.,
RA   Zdobnov E., Bork P., Suyama M., Torrents D., Alexandersson M., Trask B.J.,
RA   Young J.M., Huang H., Wang H., Xing H., Daniels S., Gietzen D., Schmidt J.,
RA   Stevens K., Vitt U., Wingrove J., Camara F., Mar Alba M., Abril J.F.,
RA   Guigo R., Smit A., Dubchak I., Rubin E.M., Couronne O., Poliakov A.,
RA   Huebner N., Ganten D., Goesele C., Hummel O., Kreitler T., Lee Y.-A.,
RA   Monti J., Schulz H., Zimdahl H., Himmelbauer H., Lehrach H., Jacob H.J.,
RA   Bromberg S., Gullings-Handley J., Jensen-Seaman M.I., Kwitek A.E.,
RA   Lazar J., Pasko D., Tonellato P.J., Twigger S., Ponting C.P., Duarte J.M.,
RA   Rice S., Goodstadt L., Beatson S.A., Emes R.D., Winter E.E., Webber C.,
RA   Brandt P., Nyakatura G., Adetobi M., Chiaromonte F., Elnitski L.,
RA   Eswara P., Hardison R.C., Hou M., Kolbe D., Makova K., Miller W.,
RA   Nekrutenko A., Riemer C., Schwartz S., Taylor J., Yang S., Zhang Y.,
RA   Lindpaintner K., Andrews T.D., Caccamo M., Clamp M., Clarke L., Curwen V.,
RA   Durbin R.M., Eyras E., Searle S.M., Cooper G.M., Batzoglou S., Brudno M.,
RA   Sidow A., Stone E.A., Payseur B.A., Bourque G., Lopez-Otin C., Puente X.S.,
RA   Chakrabarti K., Chatterji S., Dewey C., Pachter L., Bray N., Yap V.B.,
RA   Caspi A., Tesler G., Pevzner P.A., Haussler D., Roskin K.M., Baertsch R.,
RA   Clawson H., Furey T.S., Hinrichs A.S., Karolchik D., Kent W.J.,
RA   Rosenbloom K.R., Trumbower H., Weirauch M., Cooper D.N., Stenson P.D.,
RA   Ma B., Brent M., Arumugam M., Shteynberg D., Copley R.R., Taylor M.S.,
RA   Riethman H., Mudunuri U., Peterson J., Guyer M., Felsenfeld A., Old S.,
RA   Mockrin S., Collins F.S.;
RT   "Genome sequence of the Brown Norway rat yields insights into mammalian
RT   evolution.";
RL   Nature 428:493-521(2004).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RC   STRAIN=Brown Norway;
RA   Mural R.J., Adams M.D., Myers E.W., Smith H.O., Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Liver;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [6]
RP   CATALYTIC ACTIVITY, FUNCTION, SUBSTRATE SPECIFICITY, SUBCELLULAR LOCATION,
RP   AND TISSUE SPECIFICITY.
RX   PubMed=8820107;
RA   Subbaiah P.V., Liu M.;
RT   "Comparative studies on the substrate specificity of lecithin:cholesterol
RT   acyltransferase towards the molecular species of phosphatidylcholine in the
RT   plasma of 14 vertebrates.";
RL   J. Lipid Res. 37:113-122(1996).
RN   [7]
RP   CATALYTIC ACTIVITY, FUNCTION, SUBSTRATE SPECIFICITY, SUBCELLULAR LOCATION,
RP   AND MUTAGENESIS OF ALA-173.
RX   PubMed=14636062; DOI=10.1021/bi035460u;
RA   Zhao Y., Wang J., Gebre A.K., Chisholm J.W., Parks J.S.;
RT   "Negative charge at amino acid 149 is the molecular determinant for
RT   substrate specificity of lecithin: cholesterol acyltransferase for
RT   phosphatidylcholine containing 20-carbon sn-2 fatty acyl chains.";
RL   Biochemistry 42:13941-13949(2003).
CC   -!- FUNCTION: Central enzyme in the extracellular metabolism of plasma
CC       lipoproteins. Synthesized mainly in the liver and secreted into plasma
CC       where it converts cholesterol and phosphatidylcholines (lecithins) to
CC       cholesteryl esters and lysophosphatidylcholines on the surface of high
CC       and low density lipoproteins (HDLs and LDLs). The cholesterol ester is
CC       then transported back to the liver. Also produced in the brain by
CC       primary astrocytes, and esterifies free cholesterol on nascent APOE-
CC       containing lipoproteins secreted from glia and influences cerebral
CC       spinal fluid (CSF) APOE- and APOA1 levels. Together with APOE and the
CC       cholesterol transporter ABCA1, plays a key role in the maturation of
CC       glial-derived, nascent lipoproteins. Required for remodeling high-
CC       density lipoprotein particles into their spherical forms (By
CC       similarity). Has a preference for plasma 16:0-18:2 or 18:O-18:2
CC       phosphatidylcholines (PubMed:14636062, PubMed:8820107). Catalyzes the
CC       hydrolysis of 1-O-alkyl-2-acetyl-sn-glycero-3-phosphocholine (platelet-
CC       activating factor or PAF) to 1-O-alkyl-sn-glycero-3-phosphocholine
CC       (lyso-PAF) (By similarity). Also catalyzes the transfer of the acetate
CC       group from PAF to 1-hexadecanoyl-sn-glycero-3-phosphocholine forming
CC       lyso-PAF (By similarity). Catalyzes the esterification of (24S)-
CC       hydroxycholesterol (24(S)OH-C), also known as cerebrosterol to produce
CC       24(S)OH-C monoesters (By similarity). {ECO:0000250|UniProtKB:P04180,
CC       ECO:0000269|PubMed:14636062, ECO:0000269|PubMed:8820107}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=a 1,2-diacyl-sn-glycero-3-phosphocholine + a sterol = a 1-
CC         acyl-sn-glycero-3-phosphocholine + a sterol ester;
CC         Xref=Rhea:RHEA:21204, ChEBI:CHEBI:15889, ChEBI:CHEBI:35915,
CC         ChEBI:CHEBI:57643, ChEBI:CHEBI:58168; EC=2.3.1.43;
CC         Evidence={ECO:0000255|PROSITE-ProRule:PRU10037,
CC         ECO:0000269|PubMed:14636062, ECO:0000269|PubMed:8820107,
CC         ECO:0000269|PubMed:9219904};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=a 1-O-alkyl-2-acetyl-sn-glycero-3-phosphocholine + H2O = 1-O-
CC         alkyl-sn-glycero-3-phosphocholine + acetate + H(+);
CC         Xref=Rhea:RHEA:17777, ChEBI:CHEBI:15377, ChEBI:CHEBI:15378,
CC         ChEBI:CHEBI:30089, ChEBI:CHEBI:30909, ChEBI:CHEBI:36707; EC=3.1.1.47;
CC         Evidence={ECO:0000250|UniProtKB:P04180};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:17778;
CC         Evidence={ECO:0000250|UniProtKB:P04180};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-
CC         phosphocholine + H2O = (9Z,12Z)-octadecadienoate + 1-hexadecanoyl-sn-
CC         glycero-3-phosphocholine + H(+); Xref=Rhea:RHEA:40811,
CC         ChEBI:CHEBI:15377, ChEBI:CHEBI:15378, ChEBI:CHEBI:30245,
CC         ChEBI:CHEBI:72998, ChEBI:CHEBI:73002;
CC         Evidence={ECO:0000269|PubMed:14636062};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:40812;
CC         Evidence={ECO:0000305|PubMed:14636062};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=1-hexadecanoyl-2-(5Z,8Z,11Z,14Z-eicosatetraenoyl)-sn-glycero-
CC         3-phosphocholine + H2O = (5Z,8Z,11Z,14Z)-eicosatetraenoate + 1-
CC         hexadecanoyl-sn-glycero-3-phosphocholine + H(+);
CC         Xref=Rhea:RHEA:40427, ChEBI:CHEBI:15377, ChEBI:CHEBI:15378,
CC         ChEBI:CHEBI:32395, ChEBI:CHEBI:72998, ChEBI:CHEBI:73003;
CC         Evidence={ECO:0000269|PubMed:14636062};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:40428;
CC         Evidence={ECO:0000305|PubMed:14636062};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=1-hexadecanoyl-2-(5Z,8Z,11Z,14Z-eicosatetraenoyl)-sn-glycero-
CC         3-phosphocholine + cholesterol = 1-hexadecanoyl-sn-glycero-3-
CC         phosphocholine + cholesteryl (5Z,8Z,11Z,14Z)-eicosatetraenoate;
CC         Xref=Rhea:RHEA:53448, ChEBI:CHEBI:16113, ChEBI:CHEBI:72998,
CC         ChEBI:CHEBI:73003, ChEBI:CHEBI:82751;
CC         Evidence={ECO:0000269|PubMed:14636062};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:53449;
CC         Evidence={ECO:0000305|PubMed:14636062};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=1-hexadecanoyl-2-(9Z-octadecenoyl)-sn-glycero-3-phosphocholine
CC         + cholesterol = 1-hexadecanoyl-sn-glycero-3-phosphocholine +
CC         cholesteryl (9Z-octadecenoate); Xref=Rhea:RHEA:53456,
CC         ChEBI:CHEBI:16113, ChEBI:CHEBI:46898, ChEBI:CHEBI:72998,
CC         ChEBI:CHEBI:73001; Evidence={ECO:0000269|PubMed:14636062};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:53457;
CC         Evidence={ECO:0000305|PubMed:14636062};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=(24S)-hydroxycholesterol + 1-hexadecanoyl-2-acyl-sn-glycero-3-
CC         phosphocholine = (24S)-24-hydroxycholesterol ester + 1-hexadecanoyl-
CC         sn-glycero-3-phosphocholine; Xref=Rhea:RHEA:43216, ChEBI:CHEBI:34310,
CC         ChEBI:CHEBI:72998, ChEBI:CHEBI:77369, ChEBI:CHEBI:82869;
CC         Evidence={ECO:0000250|UniProtKB:P04180};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:43217;
CC         Evidence={ECO:0000250|UniProtKB:P04180};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=(24S)-hydroxycholesterol + 1-hexadecanoyl-2-(9Z,12Z-
CC         octadecadienoyl)-sn-glycero-3-phosphocholine = (24S)-
CC         hydroxycholesterol 3-linoleoate + 1-hexadecanoyl-sn-glycero-3-
CC         phosphocholine; Xref=Rhea:RHEA:43224, ChEBI:CHEBI:34310,
CC         ChEBI:CHEBI:72998, ChEBI:CHEBI:73002, ChEBI:CHEBI:82875;
CC         Evidence={ECO:0000250|UniProtKB:P04180};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:43225;
CC         Evidence={ECO:0000250|UniProtKB:P04180};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=1-hexadecanoyl-2-(8Z,11Z,14Z-eicosatrienoyl)-sn-glycero-3-
CC         phosphocholine + cholesterol = 1-hexadecanoyl-sn-glycero-3-
CC         phosphocholine + cholesteryl (8Z,11Z,14Z)-eicosatrienoate;
CC         Xref=Rhea:RHEA:53464, ChEBI:CHEBI:16113, ChEBI:CHEBI:72998,
CC         ChEBI:CHEBI:84346, ChEBI:CHEBI:86121;
CC         Evidence={ECO:0000250|UniProtKB:P04180};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:53465;
CC         Evidence={ECO:0000250|UniProtKB:P04180};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=1-hexadecanoyl-2-(5Z,8Z,11Z-eicosatrienoyl)-sn-glycero-3-
CC         phosphocholine + cholesterol = 1-hexadecanoyl-sn-glycero-3-
CC         phosphocholine + cholesteryl (5Z,8Z,11Z)-eicosatrienoate;
CC         Xref=Rhea:RHEA:53460, ChEBI:CHEBI:16113, ChEBI:CHEBI:72998,
CC         ChEBI:CHEBI:86119, ChEBI:CHEBI:88752;
CC         Evidence={ECO:0000250|UniProtKB:P04180};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:53461;
CC         Evidence={ECO:0000250|UniProtKB:P04180};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=1-hexadecanoyl-2-(5Z,8Z,11Z,14Z,17Z-eicosapentaenoyl)-sn-
CC         glycero-3-phosphocholine + cholesterol = (5Z,8Z,11Z,14Z,17Z-
CC         eicosapentaenoyl)-cholesterol + 1-hexadecanoyl-sn-glycero-3-
CC         phosphocholine; Xref=Rhea:RHEA:53468, ChEBI:CHEBI:16113,
CC         ChEBI:CHEBI:72998, ChEBI:CHEBI:84969, ChEBI:CHEBI:86137;
CC         Evidence={ECO:0000250|UniProtKB:P04180};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:53469;
CC         Evidence={ECO:0000250|UniProtKB:P04180};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-
CC         phosphocholine + cholesterol = 1-hexadecanoyl-sn-glycero-3-
CC         phosphocholine + cholesteryl (9Z,12Z)-octadecadienoate;
CC         Xref=Rhea:RHEA:53472, ChEBI:CHEBI:16113, ChEBI:CHEBI:41509,
CC         ChEBI:CHEBI:72998, ChEBI:CHEBI:73002;
CC         Evidence={ECO:0000250|UniProtKB:P04180};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:53473;
CC         Evidence={ECO:0000250|UniProtKB:P04180};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=1-hexadecanoyl-2-(6Z,9Z,12Z-octadecatrienoyl)-sn-glycero-3-
CC         phosphocholine + cholesterol = (6Z,9Z,12Z-octadecatrienoyl)-
CC         cholesterol + 1-hexadecanoyl-sn-glycero-3-phosphocholine;
CC         Xref=Rhea:RHEA:53476, ChEBI:CHEBI:16113, ChEBI:CHEBI:72998,
CC         ChEBI:CHEBI:84786, ChEBI:CHEBI:88756;
CC         Evidence={ECO:0000250|UniProtKB:P04180};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:53477;
CC         Evidence={ECO:0000250|UniProtKB:P04180};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=1-hexadecanoyl-2-(11Z,14Z,17Z-eicosatrienoyl)-sn-glycero-3-
CC         phosphocholine + cholesterol = (11Z,14Z,17Z-eicosatrienoyl)-
CC         cholesterol + 1-hexadecanoyl-sn-glycero-3-phosphocholine;
CC         Xref=Rhea:RHEA:53516, ChEBI:CHEBI:16113, ChEBI:CHEBI:72998,
CC         ChEBI:CHEBI:137411, ChEBI:CHEBI:137412;
CC         Evidence={ECO:0000250|UniProtKB:P04180};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:53517;
CC         Evidence={ECO:0000250|UniProtKB:P04180};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=1-hexadecanoyl-2-(9Z,12Z,15Z-octadecatrienoyl)-sn-glycero-3-
CC         phosphocholine + cholesterol = (9Z,12Z,15Z-octadecatrienoyl)-
CC         cholesterol + 1-hexadecanoyl-sn-glycero-3-phosphocholine;
CC         Xref=Rhea:RHEA:53520, ChEBI:CHEBI:16113, ChEBI:CHEBI:72998,
CC         ChEBI:CHEBI:84341, ChEBI:CHEBI:84789;
CC         Evidence={ECO:0000250|UniProtKB:P04180};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:53521;
CC         Evidence={ECO:0000250|UniProtKB:P04180};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=1-hexadecanoyl-sn-glycero-3-phosphocholine + a 1-O-alkyl-2-
CC         acetyl-sn-glycero-3-phosphocholine = 1-hexadecanoyl-2-acetyl-sn-
CC         glycero-3-phosphocholine + 1-O-alkyl-sn-glycero-3-phosphocholine;
CC         Xref=Rhea:RHEA:53636, ChEBI:CHEBI:30909, ChEBI:CHEBI:36707,
CC         ChEBI:CHEBI:72998, ChEBI:CHEBI:75219;
CC         Evidence={ECO:0000250|UniProtKB:P04180};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:53637;
CC         Evidence={ECO:0000250|UniProtKB:P04180};
CC   -!- SUBCELLULAR LOCATION: Secreted {ECO:0000269|PubMed:14636062,
CC       ECO:0000269|PubMed:8820107, ECO:0000269|PubMed:9219904}. Note=Secreted
CC       into blood plasma (PubMed:8820107). Produced in astrocytes and secreted
CC       into cerebral spinal fluid (CSF) (By similarity).
CC       {ECO:0000250|UniProtKB:P04180, ECO:0000269|PubMed:8820107}.
CC   -!- TISSUE SPECIFICITY: Detected in blood plasma (at protein level)
CC       (PubMed:8820107). {ECO:0000269|PubMed:8820107}.
CC   -!- SIMILARITY: Belongs to the AB hydrolase superfamily. Lipase family.
CC       {ECO:0000305}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; X54096; CAA38030.1; -; mRNA.
DR   EMBL; U62803; AAB65771.1; -; mRNA.
DR   EMBL; AC121465; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH473972; EDL92424.1; -; Genomic_DNA.
DR   EMBL; BC091155; AAH91155.1; -; mRNA.
DR   PIR; S11214; XXRTN.
DR   RefSeq; NP_058720.2; NM_017024.2.
DR   AlphaFoldDB; P18424; -.
DR   SMR; P18424; -.
DR   IntAct; P18424; 1.
DR   STRING; 10116.ENSRNOP00000026583; -.
DR   SwissLipids; SLP:000001728; -.
DR   ESTHER; ratno-lcat; PC-sterol_acyltransferase.
DR   GlyCosmos; P18424; 5 sites, No reported glycans.
DR   GlyGen; P18424; 5 sites.
DR   PhosphoSitePlus; P18424; -.
DR   PaxDb; 10116-ENSRNOP00000026583; -.
DR   Ensembl; ENSRNOT00055005021; ENSRNOP00055003725; ENSRNOG00055003235.
DR   GeneID; 24530; -.
DR   KEGG; rno:24530; -.
DR   UCSC; RGD:2993; rat.
DR   AGR; RGD:2993; -.
DR   CTD; 3931; -.
DR   RGD; 2993; Lcat.
DR   VEuPathDB; HostDB:ENSRNOG00000019573; -.
DR   eggNOG; KOG2369; Eukaryota.
DR   HOGENOM; CLU_037070_1_0_1; -.
DR   InParanoid; P18424; -.
DR   OrthoDB; 353098at2759; -.
DR   PhylomeDB; P18424; -.
DR   TreeFam; TF313258; -.
DR   BRENDA; 2.3.1.43; 5301.
DR   Reactome; R-RNO-8964058; HDL remodeling.
DR   PRO; PR:P18424; -.
DR   Proteomes; UP000002494; Chromosome 19.
DR   Proteomes; UP000234681; Chromosome 19.
DR   Bgee; ENSRNOG00000019573; Expressed in liver and 20 other cell types or tissues.
DR   GO; GO:0005615; C:extracellular space; ISS:UniProtKB.
DR   GO; GO:0034364; C:high-density lipoprotein particle; ISO:RGD.
DR   GO; GO:0003847; F:1-alkyl-2-acetylglycerophosphocholine esterase activity; ISO:RGD.
DR   GO; GO:0034186; F:apolipoprotein A-I binding; ISO:RGD.
DR   GO; GO:0004607; F:phosphatidylcholine-sterol O-acyltransferase activity; IDA:RGD.
DR   GO; GO:0004623; F:phospholipase A2 activity; IDA:RGD.
DR   GO; GO:0047179; F:platelet-activating factor acetyltransferase activity; ISO:RGD.
DR   GO; GO:0004771; F:sterol esterase activity; ISO:RGD.
DR   GO; GO:0046222; P:aflatoxin metabolic process; IEP:RGD.
DR   GO; GO:0042632; P:cholesterol homeostasis; ISO:RGD.
DR   GO; GO:0008203; P:cholesterol metabolic process; IDA:RGD.
DR   GO; GO:0030301; P:cholesterol transport; ISO:RGD.
DR   GO; GO:0034375; P:high-density lipoprotein particle remodeling; ISO:RGD.
DR   GO; GO:0006629; P:lipid metabolic process; IBA:GO_Central.
DR   GO; GO:0042158; P:lipoprotein biosynthetic process; ISO:RGD.
DR   GO; GO:0042157; P:lipoprotein metabolic process; IDA:RGD.
DR   GO; GO:0006656; P:phosphatidylcholine biosynthetic process; ISO:RGD.
DR   GO; GO:0046470; P:phosphatidylcholine metabolic process; ISS:UniProtKB.
DR   GO; GO:0006644; P:phospholipid metabolic process; ISO:RGD.
DR   GO; GO:0090107; P:regulation of high-density lipoprotein particle assembly; ISO:RGD.
DR   GO; GO:0046688; P:response to copper ion; IDA:RGD.
DR   GO; GO:0051384; P:response to glucocorticoid; IDA:RGD.
DR   GO; GO:0043691; P:reverse cholesterol transport; ISO:RGD.
DR   GO; GO:0034372; P:very-low-density lipoprotein particle remodeling; ISO:RGD.
DR   Gene3D; 3.40.50.1820; alpha/beta hydrolase; 3.
DR   InterPro; IPR029058; AB_hydrolase.
DR   InterPro; IPR003386; LACT/PDAT_acylTrfase.
DR   PANTHER; PTHR11440; LECITHIN-CHOLESTEROL ACYLTRANSFERASE-RELATED; 1.
DR   PANTHER; PTHR11440:SF18; PHOSPHATIDYLCHOLINE-STEROL ACYLTRANSFERASE; 1.
DR   Pfam; PF02450; LCAT; 1.
DR   SUPFAM; SSF53474; alpha/beta-Hydrolases; 1.
DR   PROSITE; PS00120; LIPASE_SER; 1.
PE   1: Evidence at protein level;
KW   Acyltransferase; Cholesterol metabolism; Disulfide bond; Glycoprotein;
KW   Hydrolase; Lipid metabolism; Reference proteome; Secreted; Signal;
KW   Steroid metabolism; Sterol metabolism; Transferase.
FT   SIGNAL          1..24
FT                   /evidence="ECO:0000250|UniProtKB:P04180"
FT   CHAIN           25..440
FT                   /note="Phosphatidylcholine-sterol acyltransferase"
FT                   /id="PRO_0000017806"
FT   ACT_SITE        205
FT                   /note="Nucleophile"
FT                   /evidence="ECO:0000250|UniProtKB:P04180"
FT   ACT_SITE        369
FT                   /note="Charge relay system"
FT                   /evidence="ECO:0000250|UniProtKB:P04180"
FT   ACT_SITE        401
FT                   /note="Charge relay system"
FT                   /evidence="ECO:0000250|UniProtKB:P04180"
FT   SITE            173
FT                   /note="Determinant for substrate specificity"
FT                   /evidence="ECO:0000305|PubMed:14636062"
FT   CARBOHYD        44
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        108
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        296
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        397
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        408
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   DISULFID        74..98
FT                   /evidence="ECO:0000250|UniProtKB:P04180"
FT   DISULFID        337..380
FT                   /evidence="ECO:0000250|UniProtKB:P04180"
FT   MUTAGEN         173
FT                   /note="A->E: Reduced activity with 20-carbon
FT                   phosphatidylcholine as substrate. Little change with 18-
FT                   carbon phosphatidylcholine as substrate."
FT                   /evidence="ECO:0000269|PubMed:14636062"
FT   CONFLICT        146
FT                   /note="H -> N (in Ref. 1; CAA38030)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        383
FT                   /note="W -> V (in Ref. 1; CAA38030)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        390
FT                   /note="A -> G (in Ref. 1; CAA38030)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        395
FT                   /note="P -> R (in Ref. 1; CAA38030)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        423
FT                   /note="R -> P (in Ref. 1; CAA38030)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        438..439
FT                   /note="TK -> PT (in Ref. 1; CAA38030)"
FT                   /evidence="ECO:0000305"
SQ   SEQUENCE   440 AA;  49882 MW;  836BB2D589F72B63 CRC64;
     MGLPGSPWQW VLLLLGLLLP PATSFWLLNV LFPPHTTPKA ELSNHTRPVI LVPGCMGNRL
     EAKLDKPNVV NWLCYRKTED FFTIWLDFNM FLPLGVDCWI DNTRVVYNRS SGHMSNAPGV
     QIRVPGFGKT YSVEYLDDNK LAGYLHTLVQ NLVNNGYVRD ETVRAAPYDW RLAPRQQDEY
     YQKLAGLVEE MYAAYGKPVF LIGHSLGCLH VLHFLLRQPQ SWKDHFIDGF ISLGAPWGGS
     IKPMRILASG DNQGIPIMSN IKLREEQRIT TTSPWMFPAH HVWPEDHVFI STPNFNYTGQ
     DFERFFADLH FEEGWHMFLQ SRDLLAGLPA PGVEVYCLYG VGMPTAHTYI YDHNFPYKDP
     VAALYEDGDD TVATRSTELC GQWQGRQSQA VHLLPMNGTD HLNMVFSNKT LEHINAILLG
     AYRHGTPKSP TASLGPPTKE
//
